Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-BLISOVI FE vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Acne vulgaris (off-label)
Prevention of pregnancy
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Hepatic via CYP3A4 (ethinyl estradiol) and primarily conjugation (norethindrone); first-pass metabolism.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%)
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Ethinyl estradiol: 95-98% bound to albumin and sex hormone-binding globulin (SHBG)
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Ethinyl estradiol: 2-5 L/kg; indicates extensive tissue distribution
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: ethinyl estradiol approximately 40-50% (first-pass metabolism)
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No dose adjustment required in renal impairment. Use with caution if severe renal impairment or nephrotic syndrome due to potential fluid retention.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Not recommended in moderate impairment (Child-Pugh B) without specialist advice. No data for mild (Child-Pugh A); use caution.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Not indicated in pediatric patients before menarche. For postmenarchal females, same adult dose may be used; weight-based dosing not established.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated in postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thrombotic events and comorbidities.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (DVT, PE, stroke, MI),Carcinoma (breast, cervical, liver),Hepatic disease (jaundice, cholestasis),Hypertension,Carbohydrate/lipid effects,Headache/migraine,Bleeding irregularities,Drug interactions (CYP3A4 inducers/inhibitors),Depression,Gallbladder disease,Hereditary angioedema
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Venous or arterial thrombotic/thromboembolic events (current or history),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Uncontrolled hypertension,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Headache with focal neurological symptoms or migraine with aura (age ≥35),Current or history of breast cancer or other estrogen-sensitive neoplasia,Hepatic adenomas or malignant liver tumors,Acute or chronic liver disease with abnormal function,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Cigarette smoking in women >35 years,Hypersensitivity to any component
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
Grapefruit juice may increase estrogen levels and risk of adverse effects; avoid large quantities. Iron absorption is enhanced by vitamin C (e.g., orange juice) and inhibited by tannins (tea, coffee), calcium (dairy), and phytates (whole grains); separate iron intake from these foods by at least 2 hours. Take with food to reduce GI upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-trimester exposure, and potential feminization of male fetuses from progestin exposure. Post-conception use is not indicated; if exposure occurs, evaluate for pregnancy.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Small amounts of progestins and estrogens are excreted in breast milk; M/P ratio not established for this specific formulation. Use in breastfeeding women is generally not recommended due to potential effects on milk production and composition, and possible long-term effects on the infant. Alternative contraception methods are advised until weaning.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
Contraindicated in pregnancy. If pregnancy occurs, discontinue immediately. No dose adjustment is applicable as the drug should not be used in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) are irrelevant due to contraindication.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
LO-BLISOVI FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is a combined oral contraceptive with iron supplementation. The iron component (75 mg ferrous fumarate) compensates for menstrual blood loss. Administer at the same time daily to maintain stable hormone levels. Missed doses increase risk of breakthrough bleeding and contraceptive failure. Consider non-oral contraceptives in patients with malabsorption or vomiting.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one tablet daily at the same time with food to reduce nausea.,Missed doses: if one dose is missed >12 hours, take it immediately and continue; if two doses are missed, take two tablets and use backup contraception for 7 days.,Iron tablets may cause dark stools; this is harmless.,Report severe headache, chest pain, leg swelling, or vision changes immediately.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Store in original blister pack; do not remove desiccant.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-BLISOVI FE vs LARIN 1.5/30, answered by our medical review team.
LO-BLISOVI FE is a Combination Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-BLISOVI FE and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-BLISOVI FE is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-BLISOVI FE and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-BLISOVI FE is classified as Category C. Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-tri. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.